�鶹��

Available for over a year

A major trial of an experimental dementia drug has shown - for the first time - that the progression of early stage Alzheimer’s disease can be slowed down. Nearly 2,000 people took part in the trial, in which the drug - called Lecanemab - was infused into the body every two weeks. Researchers found it slowed cognitive decline in patients with early stage Alzheimer’s by about a quarter over eighteen months. Kate Lee is the Chief Executive of the Alzheimer's Society in the UK. She told Newsday: “It’s not a cure and it can’t reverse the effects of Alzheimer’s…it can slow down the progression of the disease if we catch it very early in people.” (Picture: Shows CAT scans of brain impacted by Alzheimer's disease. Credit: Getty Images.)